AR105947A1 - Composición farmacéutica oftálmica de liberación prolongada y método para estabilizar una droga contenida en una preparación de depósito oftálmica - Google Patents

Composición farmacéutica oftálmica de liberación prolongada y método para estabilizar una droga contenida en una preparación de depósito oftálmica

Info

Publication number
AR105947A1
AR105947A1 ARP160100718A ARP160100718A AR105947A1 AR 105947 A1 AR105947 A1 AR 105947A1 AR P160100718 A ARP160100718 A AR P160100718A AR P160100718 A ARP160100718 A AR P160100718A AR 105947 A1 AR105947 A1 AR 105947A1
Authority
AR
Argentina
Prior art keywords
ophthalmic
preparation according
polyethylene glycol
deposit
stabilize
Prior art date
Application number
ARP160100718A
Other languages
English (en)
Inventor
Yamada Kazuhito
Fujisawa Toyomi
Okabe Komei
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of AR105947A1 publication Critical patent/AR105947A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicación 1: Una preparación de depósito oftálmica caracterizada porque comprende benzoato de bencilo y/o alcohol bencílico y polietilenglicol y/o dimetilsulfóxido, donde la proporción en volumen entre el benzoato de bencilo y/o el alcohol bencílico y el polietilenglicol y/o el dimetilsulfóxido en la preparación de deposito oftálmica es de entre 75:25 y 25:75 y la cantidad total de benzoato de bencilo y/o alcohol bencílico y polietilenglicol y/o dimetilsulfóxido contenida es de 50%(p/p) o más. Reivindicación 2: La preparación de depósito oftálmica de acuerdo con la reivindicación 1, caracterizada porque también contiene una droga. Reivindicación 3: La preparación de depósito oftálmica de acuerdo con la reivindicación 2, caracterizada porque la droga es un compuesto representado por la fórmula (1) donde R¹ representa un átomo de hidrógeno, un átomo halógeno, un grupo hidroxilo, un grupo alquilo C₁₋₆, un grupo alquilo C₁₋₆ sustituido con uno o más átomos halógenos, un grupo alcoxilo C₁₋₆ o un grupo alcoxilo C₁₋₆ sustituido con uno o más átomos halógenos, y R² representa un átomo de hidrógeno, un grupo alquilo C₁₋₆, un grupo alquilcarbonilo C₁₋₆ o un grupo alquilcarbonilo C₁₋₆ sustituido con uno o más grupos hidroxilo, o bien es una sal de un compuesto de este tipo. Reivindicación 6: La preparación de depósito oftálmica de acuerdo con la reivindicación 3, caracterizada porque el compuesto representado por la fórmula (1) es la 2-[[[2-[(hidroxiacetil]amino]-4-piridinil]metil]tio]-N-[4-(trifluorometoxi)fenil]-3-piridincarboxamida o una sal de esta. Reivindicación 18: La preparación de depósito oftálmica de acuerdo con cualquiera de las reivindicaciones 2 a 17, caracterizada porque es apropiada para prevenir y/o tratar una enfermedad ocular.
ARP160100718A 2015-03-18 2016-03-17 Composición farmacéutica oftálmica de liberación prolongada y método para estabilizar una droga contenida en una preparación de depósito oftálmica AR105947A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015055196 2015-03-18

Publications (1)

Publication Number Publication Date
AR105947A1 true AR105947A1 (es) 2017-11-29

Family

ID=56919076

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160100718A AR105947A1 (es) 2015-03-18 2016-03-17 Composición farmacéutica oftálmica de liberación prolongada y método para estabilizar una droga contenida en una preparación de depósito oftálmica

Country Status (12)

Country Link
US (1) US11090296B2 (es)
EP (1) EP3272362B1 (es)
JP (2) JP2016175900A (es)
KR (2) KR20230104762A (es)
CN (1) CN107427587A (es)
AR (1) AR105947A1 (es)
CA (1) CA2979971A1 (es)
ES (1) ES2969514T3 (es)
HK (2) HK1245083A1 (es)
RU (1) RU2704813C2 (es)
TW (1) TWI731853B (es)
WO (1) WO2016148228A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR105947A1 (es) * 2015-03-18 2017-11-29 Santen Pharmaceutical Co Ltd Composición farmacéutica oftálmica de liberación prolongada y método para estabilizar una droga contenida en una preparación de depósito oftálmica
EP3478285A4 (en) 2016-06-30 2020-07-22 Durect Corporation DEPOSIT FORMULATIONS
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
EA201990127A1 (ru) * 2016-12-30 2020-08-18 Дьюрект Корпорейшн Депо-препарат
WO2019213330A1 (en) 2018-05-01 2019-11-07 Idrop, Inc. Liquid depot for non-invasive sustained delivery of agents to the eye
CN112423740A (zh) * 2018-05-01 2021-02-26 奇比有限公司 用于将药物持续递送至视网膜的滴眼剂制剂和方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001388A (en) * 1973-06-14 1977-01-04 Alza Corporation Ophthalmological bioerodible drug dispensing formulation
US5980945A (en) * 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US20050281879A1 (en) * 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles
CA2555712C (en) * 2004-02-17 2013-04-23 Santen Pharmaceutical Co., Ltd. Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein
MX344532B (es) 2004-10-01 2016-12-19 Ramscor Inc Composiciones de farmaco de liberacion sostenida convenientemente implantables.
BRPI0516308A2 (pt) 2004-10-04 2010-06-15 Qlt Usa Inc composição fluida, métodos de tratamento de uma doença ou disfunção, métodos de liberação local ou sistêmica de um agente biológico, implantes, método de formação de um implante, kit de agente biológico e usos de uma composição fluida
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
CA2597590A1 (en) * 2005-02-09 2006-08-17 Macusight, Inc. Formulations for ocular treatment
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US20080287464A1 (en) 2007-05-18 2008-11-20 Wright Jeremy C Depot Formulations
CN101827523A (zh) * 2007-08-16 2010-09-08 马库赛特公司 用于治疗眼部疾病或病症的制剂
CA2767992C (en) 2009-07-17 2017-03-21 Santen Pharmaceutical Co., Ltd. 2 - [[[2 -[(hydroxyacetyl) amino]- 4 -pyridinyl] methyl] thio]- n -[4 - (trifluoromethoxy) phenyl]- 3 -pyridinecarboxamide benzenesulfonate, crystal of same, crystal polymorph thereof, and methods for production thereof
AU2012304909B2 (en) * 2011-06-10 2017-06-08 Icon Bioscience, Inc. Sustained release formulations for delivery of proteins to the eye and methods of preparing same
WO2013153559A1 (en) 2012-04-09 2013-10-17 Scidose, Llc Fulvestrant formulations
JP5856264B2 (ja) * 2013-09-20 2016-02-09 参天製薬株式会社 ポリエチレングリコール含有組成物
JP2016104708A (ja) * 2014-12-01 2016-06-09 参天製薬株式会社 アスコルビン酸誘導体を含有する非水性注射剤及びデポ形成方法
AR105947A1 (es) * 2015-03-18 2017-11-29 Santen Pharmaceutical Co Ltd Composición farmacéutica oftálmica de liberación prolongada y método para estabilizar una droga contenida en una preparación de depósito oftálmica
EP3478285A4 (en) * 2016-06-30 2020-07-22 Durect Corporation DEPOSIT FORMULATIONS
US10682340B2 (en) * 2016-06-30 2020-06-16 Durect Corporation Depot formulations

Also Published As

Publication number Publication date
CA2979971A1 (en) 2016-09-22
RU2017134354A (ru) 2019-04-03
EP3272362A4 (en) 2018-12-05
WO2016148228A1 (ja) 2016-09-22
JP2016175900A (ja) 2016-10-06
EP3272362B1 (en) 2023-12-13
KR20170129170A (ko) 2017-11-24
JP6955604B2 (ja) 2021-10-27
TW201639569A (zh) 2016-11-16
RU2017134354A3 (es) 2019-04-19
TWI731853B (zh) 2021-07-01
US11090296B2 (en) 2021-08-17
CN107427587A (zh) 2017-12-01
HK1246641A1 (zh) 2018-09-14
HK1245083A1 (zh) 2018-08-24
EP3272362A1 (en) 2018-01-24
JP2020117522A (ja) 2020-08-06
US20180042907A1 (en) 2018-02-15
KR20230104762A (ko) 2023-07-10
RU2704813C2 (ru) 2019-10-31
ES2969514T3 (es) 2024-05-21

Similar Documents

Publication Publication Date Title
AR105947A1 (es) Composición farmacéutica oftálmica de liberación prolongada y método para estabilizar una droga contenida en una preparación de depósito oftálmica
PE20191005A1 (es) 1,2,4-triazolonas 2,4,5-trisustituidas
AR069764A1 (es) Derivados de aminobenzamida como agentes utiles para controlar parasitos animales
AR094629A1 (es) Azinas herbicidas
MX2021011972A (es) Derivados de 2-(feniloxi o feniltio)pirimidina como herbicidas.
AR109595A1 (es) Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1
BR112017021002B8 (pt) composição antimicrobiana, uso de uma composição, método para reduzir substancialmente ou controlar a formação de colônias microbianas sobre ou em uma superfície, sanitizantes para as mãos, produto para o cuidado de ferimentos, produto para cuidado ou higiene pessoal, produto para animais domésticos, e, lenço antimicrobiano
PE20150339A1 (es) Carboxamidas heterociclicas fungicidas
BR112017022743A2 (pt) ?composto, composição herbicida, mistura de herbicidas e método para controlar o crescimento de vegetação indesejada?
PE20180022A1 (es) Derivados de 4-metoxi-pirrol novedosos o sales de los mismos y composicion farmaceutica que comprende los mismos
MX2022006866A (es) Pirrolidinonas como herbicidas.
BR112015021027A8 (pt) compostos terapêuticos, seus usos, e composições farmacêuticas
PE20170947A1 (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1
BR112017020094A2 (pt) composto, composição herbicida, mistura de herbicida e método para controlar o crescimento de vegetação indesejada
AR100170A1 (es) Compuestos de diaminotriazina
ECSP11011174A (es) Derivados de sulfonamida como agentes inductores de apoptesis con selectividad por bcl-2 para el tratamiento de cáncer y enfermedades inmunes
AR100052A1 (es) Compuestos de diaminotriazina
AR087913A1 (es) Inhibidores sustituidos de n-[1-ciano-2-(fenil)etil]-2-azabiciclo[2,2,1]heptan-3-carboxamida de catepsina c
CO2018000795A2 (es) Método para preparar derivados de ácido 3-(2-anilino-1-ciclohexil-1h-bencimidazol-5-il)propanoico sustituido
PE20151509A1 (es) Derivado de piridina monociclico
AR100171A1 (es) Compuestos de diaminotriazina y su uso como herbicida
PE20211770A1 (es) 3,3-difluoroalilaminas o sales de las mismas y composiciones farmaceuticas que las comprenden
TW201613568A (en) Pharmaceutical composition comprising novel hydroxamic acid derivative or salt thereof
PE20170669A1 (es) Compuesto heterociclico
AR100328A1 (es) Moduladores pirrolidina de gpr40

Legal Events

Date Code Title Description
FB Suspension of granting procedure